British Journal of Cancer - Table of Contents alert Volume 110 Issue 12

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 110, Issue 12 (2821-3020) Published online 10 June 2014 In this issue Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Retraction Author Index Keyword Index Indexes Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Clinical Studies Top Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial B Escudier, M D Michaelson, R J Motzer, T E Hutson, J I Clark, H Y Lim, E Porfiri, P Zalewski, G Kannourakis, M Staehler, J Tarazi, B Rosbrook, L Cisar, S Hariharan, S Kim and B I Rini Br J Cancer 2014 110: 2821-2828; advance online publication, May 13, 2014; 10.1038/bjc.2014.244 Abstract | Full Text Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) E L Turner, C Metcalfe, J L Donovan, S Noble, J A C Sterne, J A Lane, K N Avery, L Down, E Walsh, M Davis, Y Ben-Shlomo, S E Oliver, S Evans, P Brindle, N J Williams, L J Hughes, E M Hill, C Davies, S Y Ng, D E Neal, F C Hamdy, R M Martin and the CAP trial group Br J Cancer 2014 110: 2829-2836; advance online publication, May 27, 2014; 10.1038/bjc.2014.242 Abstract | Full Text Sentinel lymph node biopsy in vulval cancer: systematic review and meta-analysis C Meads, A J Sutton, A N Rosenthal, S Małysiak, M Kowalska, A Zapalska, E Rogozińska, P Baldwin, R Ganesan, E Borowiack, P Barton, T Roberts, K Khan and S Sundar Br J Cancer 2014 110: 2837-2846; advance online publication, May 27, 2014; 10.1038/bjc.2014.205 Abstract | Full Text Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer D K Woolf, M Beresford, S P Li, M Dowsett, B Sanghera, W L Wong, L Sonoda, S Detre, V Amin, M-L Ah-See, D Miles and A Makris Br J Cancer 2014 110: 2847-2854; advance online publication, May 15, 2014; 10.1038/bjc.2014.207 Abstract | Full Text Translational Therapeutics Top Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer C-L Soh, K McNeil, C M Owczarek, M P Hardy, L J Fabri, M Pearse, C A Delaine and B E Forbes Br J Cancer 2014 110: 2855-2864; advance online publication, May 22, 2014; 10.1038/bjc.2014.232 Abstract | Full Text Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells M Mancini, M B Gariboldi, E Taiana, M C Bonzi, I Craparotta, M Pagin and E Monti Br J Cancer 2014 110: 2865-2873; advance online publication, May 22, 2014; 10.1038/bjc.2014.269 Abstract | Full Text MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases E Nagy, K B Gajjar, I I Patel, S Taylor, P L Martin-Hirsch, H F Stringfellow, F L Martin and D H Phillips Br J Cancer 2014 110: 2874-2880; advance online publication, May 22, 2014; 10.1038/bjc.2014.263 Abstract | Full Text X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary M Miyamoto, M Takano, K Iwaya, N Shinomiya, M Kato, T Aoyama, N Sasaki, T Goto, A Suzuki, J Hitrata and K Furuya Br J Cancer 2014 110: 2881-2886; advance online publication, May 22, 2014; 10.1038/bjc.2014.255 Abstract | Full Text The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models V D'Amato, R Rosa, C D'Amato, L Formisano, R Marciano, L Nappi, L Raimondo, C Di Mauro, A Servetto, C Fusciello, B M Veneziani, S De Placido and R Bianco Br J Cancer 2014 110: 2887-2895; advance online publication, May 13, 2014; 10.1038/bjc.2014.241 Abstract | Full Text Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925 X Yang, P Yang, J Shen, E Osaka, E Choy, G Cote, D Harmon, Z Zhang, H Mankin, F J Hornicek and Z Duan Br J Cancer 2014 110: 2896-2904; advance online publication, May 22, 2014; 10.1038/bjc.2014.254 Abstract | Full Text Molecular Diagnostics Top Cdc20 and securin overexpression predict short-term breast cancer survival H Karra, H Repo, I Ahonen, E Löyttyniemi, R Pitkänen, M Lintunen, T Kuopio, M Söderström and P Kronqvist Br J Cancer 2014 110: 2905-2913; advance online publication, May 22, 2014; 10.1038/bjc.2014.252 Abstract | Full Text Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer N Cihoric, S Savic, S Schneider, I Ackermann, M Bichsel-Naef, R A Schmid, D Lardinois, M Gugger, L Bubendorf, I Zlobec and C Tapia Br J Cancer 2014 110: 2914-2922; advance online publication, May 22, 2014; 10.1038/bjc.2014.229 Abstract | Full Text Tropomyosin-related receptor kinase B at the invasive front and tumour cell dedifferentiation in gastric cancer K Tanaka, T Shimura, T Kitajima, S Kondo, S Ide, Y Okugawa, S Saigusa, Y Toiyama, Y Inoue, T Araki, K Uchida, Y Mohri and M Kusunoki Br J Cancer 2014 110: 2923-2934; advance online publication, May 22, 2014; 10.1038/bjc.2014.228 Abstract | Full Text Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer I J Goossens-Beumer, E C M Zeestraten, A Benard, T Christen, M S Reimers, R Keijzer, C F M Sier, G J Liefers, H Morreau, H Putter, A L Vahrmeijer, C J H van de Velde and P J K Kuppen Br J Cancer 2014 110: 2935-2944; advance online publication, May 1, 2014; 10.1038/bjc.2014.226 Abstract | Full Text MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9 A Y Jia, M Castillo-Martin, D M Bonal, M Sánchez-Carbayo, J M Silva and C Cordon-Cardo Br J Cancer 2014 110: 2945-2954; advance online publication, May 13, 2014; 10.1038/bjc.2014.245 Abstract | Full Text Direct T cell–tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme P Jin, S Civini, Y Zhao, V De Giorgi, J Ren, M Sabatino, J Jin, H Wang, D Bedognetti, F Marincola and D Stroncek Br J Cancer 2014 110: 2955-2964; advance online publication, May 8, 2014; 10.1038/bjc.2014.235 Abstract | Full Text Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor H Nishio, T Yaguchi, J Sugiyama, H Sumimoto, K Umezawa, T Iwata, N Susumu, T Fujii, N Kawamura, A Kobayashi, J Park, D Aoki and Y Kawakami Br J Cancer 2014 110: 2965-2974; advance online publication, May 27, 2014; 10.1038/bjc.2014.251 Abstract | Full Text Genetics and Genomics Top Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer A Koussounadis, S P Langdon, D J Harrison and V A Smith Br J Cancer 2014 110: 2975-2984; advance online publication, May 27, 2014; 10.1038/bjc.2014.258 Abstract | Full Text Multi-colour FISH in oesophageal adenocarcinoma—predictors of prognosis independent of stage and grade C-I Geppert, P Rümmele, M Sarbia, R Langer, M Feith, L Morrison, E Pestova, R Schneider-Stock, A Hartmann and T T Rau Br J Cancer 2014 110: 2985-2995; advance online publication, May 22, 2014; 10.1038/bjc.2014.238 Abstract | Full Text Retraction Top Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies D Tural, S Serdengecti, F Demirelli, T Öztürk, S İlvan, H Turna, M Özgüroglu and E Büyükünal Br J Cancer 2014 110: 2996; 10.1038/bjc.2014.314 Full Text Author Index Top Author Index for Volume 110 Br J Cancer 2014 110: 2997-3006; 10.1038/bjc.2014.319 Full Text Keyword Index Top Keyword Index for Volume 110 Br J Cancer 2014 110: 3007-3011; 10.1038/bjc.2014.320 Full Text Indexes Top Referee Acknowledgement for 2013 Br J Cancer 2014 110: 3012-3020; 10.1038/bjc.2014.321 Full Text Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.